Evolus, Inc.
General ticker "EOLS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $383.5M (TTM average)
Evolus, Inc. follows the US Stock Market performance with the rate: 41.3%.
Estimated limits based on current volatility of 3.2%: low 7.23$, high 7.71$
Factors to consider:
- Total employees count: 334 (+0.6%) as of 2025
- US accounted for 95.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Significant losses, Market competition, Economic downturns and volatility, Regulatory and compliance, Cybersecurity threats
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.47$, 10.35$]
- 2026-12-31 to 2027-12-31 estimated range: [4.42$, 10.18$]
Financial Metrics affecting the EOLS estimates:
- Positive: with PPE of -13.2 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Positive: -13.52 < Operating profit margin, % of -9.71
- Negative: Shareholder equity ratio, % of -10.23 <= 7.04
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Inventory ratio change, % of 5.71 > 4.02
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Negative: 2.54 < Interest expense per share per price, % of 4.48
Short-term EOLS quotes
Long-term EOLS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $197.83MM | $259.10MM | $303.56MM |
| Operating Expenses | $247.06MM | $293.51MM | $336.22MM |
| Operating Income | $-49.23MM | $-34.41MM | $-32.66MM |
| Non-Operating Income | $-12.28MM | $-15.35MM | $-18.30MM |
| Interest Expense | $13.83MM | $18.73MM | $19.69MM |
| R&D Expense | $15.43MM | $9.17MM | $9.58MM |
| Income(Loss) | $-61.51MM | $-49.76MM | $-50.96MM |
| Taxes | $0.18MM | $0.66MM | $0.68MM |
| Net Income(Loss)* | $-61.69MM | $-50.42MM | $-51.64MM |
| Stockholders Equity | $-20.69MM | $5.52MM | $-23.11MM |
| Inventory | $11.00MM | $12.16MM | $26.96MM |
| Assets | $189.00MM | $232.57MM | $225.87MM |
| Operating Cash Flow | $-34.01MM | $-18.00MM | $-42.27MM |
| Capital expenditure | $1.63MM | $1.47MM | $8.45MM |
| Investing Cash Flow | $-1.63MM | $-4.82MM | $-8.45MM |
| Financing Cash Flow | $44.64MM | $47.41MM | $17.34MM |
| Earnings Per Share** | $-1.08 | $-0.81 | $-0.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.